Sunshine Biopharma (Sunshine Biopharma) Debt-to-Asset : 0.02 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma Debt-to-Asset?

Sunshine Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.12 Mil. Sunshine Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.54 Mil. Sunshine Biopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $27.35 Mil. Sunshine Biopharma's debt to asset for the quarter that ended in Dec. 2023 was 0.02.

Sunshine Biopharma Debt-to-Asset Historical Data

The historical data trend for Sunshine Biopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Debt-to-Asset Chart

Sunshine Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

7.31

1.83

0.86

0.03

0.02

Sunshine Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.03	0.03	0.03	0.02	0.02

Competitive Comparison of Sunshine Biopharma's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunshine Biopharma's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's Debt-to-Asset falls into.

Sunshine Biopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sunshine Biopharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.119	+	0.539)	/	27.347
	=	0.02

Sunshine Biopharma's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.119	+	0.539)	/	27.347
	=	0.02

Sunshine Biopharma (NAS:SBFM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sunshine Biopharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunshine Biopharma (Sunshine Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5

Website

https://www.sunshinebiopharma.com

Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).

Executives

Camille Sebaaly	director, officer: CFO and Secretary	14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun	10 percent owner	1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan	director	11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller	director	10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey	director	6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish	director	6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah	director	924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp	10 percent owner	579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty	director, 10 percent owner, officer: CEO and President	579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki	director, officer: Chief Operating Officer	731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di	director, officer: Chief Operating Officer	3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3